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Section A 
Short Essay Questions 
Total Number of Marks for this section: 90 Marks  
 
This section should be answered in the Answer Booklet provided. 
 
Marks for each question are indicated.  




a) Outline the distribution of sodium in human body. 
b) Briefly identify the roles of serum sodium level in current healthcare practice. 




a)  Briefly describe how these renal function tests (Urea, Cr, and eGFR) can be 
utilised for the diagnosis and monitoring of the following common kidney 
disorders: (i) acute renal failure (acute kidney injury), and (ii) chronic renal 
failure (chronic kidney disease)? 
b)  Comment on the following results for Mr X’s renal function test.  
• Urea 12.5 
• Serum Cr 132 
• eGFR 50 
Mr X is a 51 year-old overweight male (102 kg) with no medical disease and 
not taking any medication. However, he has a family history of type II diabetes 
mellitus. Mr X is currently suffering from acute diarrhoea due to food 
poisoning. 




Discuss the common mechanisms which can cause each of these following 
disturbances. Give examples to illustrate your answers in each scenario. 
• Hyperkalaemia 
• Hyperosmolality 
 (5 + 5 = 10 Marks) 
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Question 4 
Briefly discuss any THREE of the following biochemistry tests. What information can 
they provide in regard to the health of an individual? Give examples to illustrate your 
answer. 
• Bilirubin – in liver function test 
• NT-proBNP – in cardiac function test 
• Plasma cortisol – in adrenal function test 
• ALT  – in liver function test 




Discuss any TWO of the following biochemistry tests. What information can they 
provide in regard to the health of an individual? Give examples to illustrate your 
answer. 
• Troponin T 
• Fasting LDL 
• TSH 




a)  What can these routine tests for diabetes (BGL, HbA1c, glucose tolerance 
test) tell you about the potential health issue(s) of a young adult? 
b)  Comment on the following results for Mrs Y’s routine diabetes test. She is a 49 
year-old female with a history of type II diabetes mellitus and she is taking 
metformin to manage condition. She is a smoker, and she is about to have a 
surgery to repair her right knee that she injured during a sporting accident. 
• Fasting BGL 8.9 
• HbA1c 7.2 
• eGFR  76 
(6 + 7 = 13 Marks) 
 
 
THIS EXAMINATION PAPER AND SUPPLIED MATERIALS ARE NOT PERMITTED TO BE REMOVED FROM 
ANY EXAMINATION VENUE IN ANY CIRCUMSTANCE 
 
Semester 1, 2015 FINAL EXAMINATION 
 PHA311 – Clinical Biochemistry 
Page 4 of 12  
Question 7 
a) List and describe the common causes for variations in the clinical laboratory 
test results. 
b) Explain the properties of an ideal marker to distinguish health and disease 
states in humans. 
(7.5 + 7.5 = 15 Marks) 
 
(Total Marks for Section A: 90 Marks) 
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Section B 
Case Study Based Questions 
Total Number of Marks for this section: 90 Marks 
 
This section should be answered in the Answer Booklet provided. 
 
Marks for each question are indicated.  




Mrs AA is a 60 year-old female, who presents to her GP (Dr X) complaining of 
nausea and general unwell. Mrs AA has hypertension, type II diabetes mellitus, and 
chronic renal failure (Baseline Cr ~ 150 micromol/L).  
The initial physical examination indicate that Mrs AA is dis-orientated and has an 
elevated blood pressure (173/ 103). During the examination, she also vomits and 
lose consciousness. Mrs AA is quickly transferred to the hospital for the urgent 
investigation and treatment. The doctor also orders a full electrolyte panel, full blood 
panel, liver function tests, and BSL. The results are as follow: 
U&E FBE 
Na 154 Hb 176 
K 3.5 RCC 5.9 
Cl 116 Hct 0.55 
Urea 15.7 MCV 94 
Cr 216 WCC 25.9 
eGFR 20 Platelet 417 
Ca (total) 2.84 Others  
Mg 1.52 INR 1.2 
Phosphate 1.52 Lipase 122 
Bicarbonate 10 Serum Osmo 393 
LFT  BSL (random) 49.8 
ALP 107   
ALT 32   
AST 38   
GGT 36   
Alb 38   
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Questions 
a) What do the serum osmolality and U&E results indicate/ suggest? Discuss 
whether this indication matches with Mrs AA’s current clinical presentation. 
(10 Marks) 
 
b) What are the likely reasons that can contribute to this condition in Mrs AA? 
(5 Marks) 
 
c) What do the other laboratory results (LFT, FBE, others) indicate/ suggest? 
Discuss whether this indication(s) matches with Mrs AA’s clinical presentation 




d) What other biochemistry test(s) would you recommend to help confirm or 
exclude the potential diagnosis identified in Question A and Question C? 
Justify your recommendation and explain what finding will be the most useful. 
(6 Marks) 
 
e) During and after an appropriate treatment is introduced, what biochemistry 
test(s) would you recommend to monitor Mrs AA’s progression? Justify your 
recommendation and explain how the test(s) should be used. 
(6 Marks) 
(Total marks for Question 8: 33 marks) 
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Question 9 
Case 2 
Mrs BB is a 63 year-old retired teacher. She is overweight (96 kg, 163 cm tall), and is 
a current smoker. She has a yearly check-up with her GP. In June last year (2014), 
Mrs BB mentioned that she was feeling ‘depress’ and ‘lack of energy’ in the previous 
months. She was diagnosed with hypertension and diabetes (Type II) a few years 
ago, and is currently treated with prescription medications.  
Her regular medications are enalapril and gliclazide. However, she does not belief in 
modern medicine and often forgets to take her medication. 
Note: (a) enalapril is an ACE-inhibitor (angiotensin-ii converting enzyme Inhibitor) 
which inhibits the conversion of angiotensin-I to angiotensin-II of the renin- 
angiotensin- aldosterone (RAA) regulatory system; (b) gliclazide is a sulfonylurea 
which stimulates insulin secretion from functional pancreatic β-cells. 
As part of the check-up, her doctor ordered a few blood tests. The blood test results 
are as follow.  
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Hb 100 115  138  145 
RCC 3.9 4.3  4.6  4.9 
Hct 30 42    43 
MCV 77 97    88 
Plt 543 410  196  286 
WCC 8.9 18.6  7.4  6.9 
Neutrophil  15.1     
Lymphocyte  2.4     
Monocyte  0.9     
Na  144   142 138 
K  4.4   4.1 3.9 
Cl  108   101 99 
Urea  7.1   8.9 10.5 
Cr  70   83 91 
eGFR  74   60.4 54.1 
ALT 21     16 
ALP 51     63 
AST 27     42 
GGT 34     51 
Bilirubin (total)      10 
Albumin      38 
Total cholesterol   6.8   7.2 
LDL   4.6   5.2 
HDL   1.0   0.9 
TG   2.6   2.4 
BGL (fasting)   8.1  6.8  
        (random)  9.4    7.8 
HbA1c     8.9 9.2 
CRP  37     
TSH      16 
T4 (free)      10 
 
Questions 




b) Considering the medical history of Mrs BB for the past 4 years, discuss the 
control of Mrs BB’s diabetes. 
(8 Marks) 
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c) Considering Mrs BB’s blood test results, discuss ONE of the most likely 
diagnoses for Mrs BB? Justify your choice with reference to Mrs BB’s clinical 
presentation and her laboratory test results.  
(8 Marks) 
 
d) If appropriate treatment is initiated, what biochemistry test(s) can provide 
useful information for monitoring Mrs BB’s treatment progression? Outline how 
the tests should be utilised. 
(6 Marks) 
 
About a year after she last visited her GP, Mrs BB experiences a sudden chest pain, 
sweating, palpitation and nausea. She is brought to the hospital for emergency 














BGL (random) 8.6 
CRP 5.4 
Troponin I 2.4 
 
Questions 
e) Name the condition associated with Mrs BB’s test result on 23-July-2015. 
Briefly discuss the likely cause of this condition in Mrs BB. 
(7 Marks) 
 
(Total marks for Question 9: 34 marks)  
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Question 10 
Case 3 
Mr CC is a 23 year-old man who does not have any known medical disorder, and is 
not taking any regular medication.  
Mr CC presents to the hospital with an acute abdominal pain and severe vomiting 
that affect him for the last 2 days. He has not been able to eat or drink properly. He is 




Na 140 Hb 153 
K 3.4 RCC 5.9 
Cl 90 Hct 56 
Urea 10.7 WCC 14.1 
Cr 153 LFT 
eGFR 49.2 ALT 28 
ABG AST 41 
pH 7.55 ALP 200 
pCO2 44 GGT 72 
pO2 77 Others 
HCO3 35 BGL (random) 5.0 
SatO2 96% CRP 52 
 
Questions 
a) What do the results in his arterial blood gas (ABG) show? Explain why Mr CC 
might have developed this condition? 
(10 Marks) 
 




c) What do the other biochemistry tests (U&E, FBE, BGL and CRP) results 
indicate/ suggest? Explain your answer. 
(6 Marks) 
(Total marks in Question 10: 23 marks)  
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Reference ranges for regular lab tests used in this particular 
laboratory 
 
Urea and electrolytes (U&E) 
Na 135.0-145.0 mmol/L 
K 3.50-4.50 mmol/L (plasma) 3.8-4.9 mmol/L (serum) 
Cl 95-110 mmol/L 
Urea 3.8-8.0 mmol/L 
Creatinine 60-100 micromol/L 
eGFR > 90 mL/min/1.73 m2  
Osmolality (serum) 275-295 mOsm/kg 
Anion gap 13-17 mEq/L 
 
Calcium, magnesium and phosphate (CMP) 
Ca (total) 2.1-2.6 mmol/L 
Ca (ionised) 1.16-1.3 mmol/L 
PO43-  0.8-1.5 mmol/L 
Mg 0.8-1.0 mmol/L 
 
Arterial blood gas (ABG) 
pH 7.35-7.45 
pO2 80-110 mmHg 
pCO2 35-45 mmHg 
Bicarbonate (HCO3-) 22-33 mmol/L 
 
Full blood examination (FBE) 
Hb 140-174 (male); 120-160 (female) g/L 
RCC 4.50-5.50 (male); 4.0-5.0 (female) x10 12 /L 
Haematocrit 42-52 % (male); 36-48% (female) 
MCV 80.0-100.0 fL 
RDW 11.5-14.5 % 
Platelets 150-450 (x10 9 /L) 
WCC 4.0-11.0 (x10 9 /L) 
Neutrophil 40-80%; or2.0-7.5 (x10 9 /L) 
Lymphocytes 20-40%; or 1.5-4.0 (x10 9 /L) 
Monocytes 2-10%; or 0.2-0.8 (x10 9 /L) 
Eosinophils 1-6%; or 0.0-0.4 (x10 9 /L) 
Basophils <2%; or 0.0-0.1 (x10 9 /L) 
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Liver function test (LFT) 
ALT <30 U/L 
AST <40 U/L 
ALP 30-100 U/L 
GGT <30 U/L (female); <50 U/L (male) 
Bilirubin (total) <20 micromol/L 
Bilirubin (conjugated) <4.0 micromol/L 
Albumin 32-45 g/L 
Total protein 63-80 g/L 
 
Thyroid function test (TFT) 
TSH 0.4-5.0 mU/L 
T4 (free) 10-25 pmol/L 
T3 (free) 3.0-6.5 pmol/L 
 
Carbohydrate metabolism 
BSL (random) 3.0-7.7 mmol/L 
BSL (fasting) 3.0-5.5 mmol/L 
HbA1c <7% * 
 
Fasting lipid biochemistry 
Total cholesterol <5.5 mmol/L 
LDL 2-3.4 mmol/L 
HDL >1 mmol/L 
Non-HDL cholesterol <2.5 mmol/L 
TG <1.7 mmol/L 
 
Others 
Troponin T <0.01 µg/L 
CRP <3 mg/L 
D-dimer <500 µg/L 
BNP <20 nmol/L 
 
 
